Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Intellia Therapeutics (NTLA) over the last 10 years, with Q3 2025 value amounting to 0.58%.

  • Intellia Therapeutics' Return on Capital Employed fell 900.0% to 0.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.58%, marking a year-over-year decrease of 900.0%. This contributed to the annual value of 0.47% for FY2024, which is 700.0% down from last year.
  • As of Q3 2025, Intellia Therapeutics' Return on Capital Employed stood at 0.58%, which was down 900.0% from 0.6% recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Return on Capital Employed peaked at 0.23% during Q4 2021, and registered a low of 0.6% during Q2 2025.
  • For the 5-year period, Intellia Therapeutics' Return on Capital Employed averaged around 0.41%, with its median value being 0.41% (2023).
  • Its Return on Capital Employed has fluctuated over the past 5 years, first skyrocketed by 1600bps in 2021, then plummeted by -1900bps in 2022.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Return on Capital Employed stood at 0.23% in 2021, then plummeted by -73bps to 0.39% in 2022, then dropped by -14bps to 0.45% in 2023, then fell by -12bps to 0.5% in 2024, then decreased by -17bps to 0.58% in 2025.
  • Its last three reported values are 0.58% in Q3 2025, 0.6% for Q2 2025, and 0.55% during Q1 2025.